Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Consulting agrmnt
Auditor change
Credit agrmnt [a]
Director departure
Employment agrmnt

HORIZON PHARMACEUTICAL LLC (RPTP) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/31/2016 8-K Quarterly results
10/25/2016 8-K Form 8-K - Current report
10/19/2016 8-K Form 8-K - Current report
10/11/2016 8-K Form 8-K - Current report
09/12/2016 8-K Form 8-K - Current report
08/04/2016 8-K Form 8-K - Current report
07/07/2016 8-K Form 8-K - Current report
05/27/2016 8-K Form 8-K - Current report
05/13/2016 8-K Form 8-K - Current report
05/05/2016 8-K Form 8-K - Current report
03/15/2016 8-K Form 8-K - Current report
02/25/2016 8-K Quarterly results
Docs: "Raptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate Update 2015 Global Net Revenue for PROCYSBI ® of $94.2 Million Reported 2016 Global Net Revenue Guidance of $115 to $125 Million"
02/09/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Change in Control Severance Agreement"
12/10/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Raptor Plans to Advance RP103 in a Registration Study in Huntington's Disease Based on Favorable Treatment Effects at 36 Months in CYST-HD Trial"
11/05/2015 8-K Quarterly results
Docs: "Raptor Pharmaceutical Corp. Reports Third Quarter 2015 Financial Results and Provides Corporate Update Record PROCYSBI ® Product Sales of $25.8 Million Raptor Raises 2015 PROCYSBI Revenue Guidance to $90-$95 Million"
10/05/2015 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "Amended and Restated Asset Purchase Agreement, by and among Raptor Pharmaceuticals Inc., Raptor Pharmaceutical Corp. and Tripex Pharmaceuticals, LLC",
"Raptor Pharmaceutical Completes Acquisition of Quinsair™"
09/14/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Raptor Pharmaceutical Provides Topline Results from Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis"
09/09/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Risk Factors"
09/04/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Sales Agreement, between Raptor Pharmaceutical Corp. and Cowen and Company, LLC",
"Opinion of Latham & Watkins LLP"
09/04/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "ASSET PURCHASE AGREEMENT between: RAPTOR PHARMACEUTICAL CORP., a Delaware corporation; and TRIPEX PHARMACEUTICALS, LLC, a Delaware limited liability company Dated as of August 20, 2015 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission Confidential treatment has been requested with respect to portions of this agreement. CONFIDENTIAL TABLE OF CONTENTS Section Page 1. Sale of Transferred Assets and Related Matters 1 1.1 Sale of Transferred Assets 1 1.2 Excluded Assets 2 1.3 Purchase Price 2 1.4 Assumption of Certain Liabilities 3 1.5 Issuances of Purchaser Common Stock 4 1.6 Transaction Taxes 6 1.7 Allocation 6 1.8 Tax Withholding 6 1.9 Closing 7 2. Contingent Consideration 7 2.1 Milestone Payments 7 2.2 Revenue-Based ...",
"Registration Rights Agreement, by and among Raptor Pharmaceutical Corp., Tripex Pharmaceuticals, LLC and certain members of Tripex Pharmaceuticals, LLC",
"Registration Rights Agreement, by and among Raptor Pharmaceutical Corp., Tripex Pharmaceuticals, LLC and certain members of Tripex Pharmaceuticals, LLC",
"COMMERCIAL SUPPLY AGREEMENT This COMMERCIAL SUPPLY AGREEMENT , dated as of August 20, 2015 , is made between PARI PHARMA GMBH, a German corporation, with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany , and RAPTOR PHARMACEUTICALS, INC., a Delaware corporation, with a place of business at 7 Hamilton Landing, Suite 100, Novato, CA 94949 . PARI and RAPTOR are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” RECITALS WHEREAS, PARI is in the business of developing, manufacturing and commercializing, among other things, drug inhalation devices and optimized formulations used in the treatment of respiratory tract disorders. WHEREAS, RAPTOR is in the business of developing and commercializing drugs for various diseases and condit...",
"LETTER AGREEMENT This Letter Agreement dated as of August 20, 2015, is made by and between PARI PHARMA GMBH, a company organized under the laws of Germany , and RAPTOR PHARMACEUTICALS, INC., a Delaware corporation . RECITALS A. PARI GmbH, an affiliate of PARI, and MPEX Pharmaceuticals, Inc. entered into a Development and License Agreement, effective as of February 11, 2006 . The Development Agreement was subsequently assigned by PARI GmbH to PARI. B. RAPTOR is in the process of, either directly or through an affiliate, acquiring all of the assets and certain obligations of TRIPEX Pharmaceuticals, LLC, a Delaware limited liability company , including the Development Agreement . C. RAPTOR and PARI are entering into a new Supply Agreement as a condition of RAPTOR's execution of the purchase a...",
"TO THE DEVELOPMENT AND LICENSE AGREEMENT"
08/21/2015 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio with the Acquisition of Quinsair TM"
08/06/2015 8-K Quarterly results
Docs: "Raptor Pharmaceutical Corp. Reports Second Quarter 2015 Financial Results and Provides Corporate Update PROCYSBI ® Product Sales Increased 43% Year over Year to $23.3 Million in Second Quarter"
07/16/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Transition and Separation Agreement with Thomas E. Daley"
05/20/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/18/2015 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "Amendment to the Amended and Restated Bylaws of Raptor Pharmaceutical Corp. (effective as of May 18, 2015)",
"Amended and Restated Bylaws of Raptor Pharmaceutical Corp. (effective as of immediately following the 2015 Annual Meeting on May 19, 2015)"
05/07/2015 8-K Quarterly results
Docs: "Raptor Pharmaceutical Reports First Quarter 2015 Financial Results and Provides Corporate Update Reports PROCYSBI ® Sales of $20.5 Million in First Quarter Company to Host Conference Call and Webcast Today at 4:30 p.m. ET/1:30 p.m. PT"
04/03/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, among Raptor Pharmaceutical Corp. and Citigroup Global Market Inc. and Leerink Partners LLC, as representatives of the underwriters named therein",
"Opinion of Latham & Watkins LLP"
02/26/2015 8-K Quarterly results
Docs: "Raptor Pharmaceutical Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Corporate Update Global Net Product Sales for PROCYSBI ® of $69.5 Million for 2014 2015 PROCYSBI Revenue Guidance of $80-$90 Million"
02/13/2015 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Other Events
01/07/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Executive Employment Agreement, by and between Michael Smith and Raptor Pharmaceutical Corp",
"Raptor Pharmaceutical Appoints Krishna Polu, M.D. as Chief Medical Officer and Michael Smith as Chief Financial Officer"
12/18/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Raptor Pharmaceutical Appoints Gregg Lapointe and Georges Gemayel to Board of Directors"
11/06/2014 8-K Quarterly results
Docs: "Global Net Product Sales for PROCYSBI ® of $23.8 Million for Third Quarter 2014 PROCYSBI Revenue of $52.2 Million Reached Through September 2014 PROCYSBI Revenue Guidance of $65-$70 Million Maintained"
10/23/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement with Georgia Erbez",
"Raptor Pharmaceutical Announces Management Changes"
08/21/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Opinion of Latham & Watkins LLP",
"Second Amended and Restated Sales Agreement, between Raptor Pharmaceutical Corp. and Cowen and Company, LLC"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy